Summary & Overview
CPT 0183U: Navigator DI Sequencing for Diego Blood Group Antigens
CPT code 0183U identifies a Proprietary Laboratory Analyses (PLA) molecular sequencing test — the Navigator DI Sequencing assay from Grifols Immunohematology Center — that detects gene variants underlying Diego (DI) blood group antigens. The result can inform transfusion compatibility, organ transplant matching, and perinatal management by clarifying antigen status that is not captured by routine serology. Nationally, PLA codes like 0183U matter because they represent single‑manufacturer assays with specific clinical utility and unique billing considerations.
Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, typical sites of service, and which payers are relevant for coverage discussions. The publication summarizes common modifiers used with the code and notes when input data are unavailable. It also places the test in clinical context—molecular blood group typing to reduce adverse reactions in transfusion, transplantation, and maternal–newborn care—and outlines the types of benchmarks and policy updates readers can expect in the full report, including reimbursement patterns, coding guidance, and payer coverage trends.
Billing Code Overview
CPT code 0183U is a Proprietary Laboratory Analyses (PLA) code for the Navigator DI Sequencing test from Grifols Immunohematology Center. The test analyzes specific gene sequences that determine Diego (DI) blood group antigens to help clinicians identify blood‑type incompatibility risks in blood transfusion, organ transplantation, pregnancy, and care of newborns.
-
Service type: Molecular diagnostic sequencing of Diego (DI) blood group–related genes
-
Typical site of service: Clinical laboratory or reference laboratory using a blood specimen
Clinical & Coding Specifications
Clinical Context
A patient is a pregnant woman with a prior history of hemolytic disease of the fetus/newborn in a prior pregnancy and a current partner of a different ethnic background. Maternal blood is submitted for genetic typing using the Navigator DI Sequencing test to determine Diego (DI) blood group antigen genotypes. The clinical workflow: ordering clinician (obstetrician or maternal-fetal medicine specialist) places the order with relevant clinical indication; phlebotomy collects a blood specimen and ships to Grifols Immunohematology Center; laboratory performs the proprietary sequencing assay reported under 0183U; results are returned to the ordering provider and transfusion medicine or blood bank staff to inform prenatal counseling, antibody risk assessment, and transfusion or neonatal management if needed. Typical site of service is an outpatient phlebotomy collection center or hospital laboratory specimen collection with testing performed at the manufacturer's reference laboratory. The service type is a laboratory genetic sequencing assay (Proprietary Laboratory Analysis) for blood group antigen genotyping to minimize transfusion or perinatal incompatibility risks.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no other modifier applies and reporting the test normally. |